Last reviewed · How we verify
Liso-cel
Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19.
Liso-cel is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill B cells expressing CD19. Used for Relapsed or refractory large B-cell lymphoma, Relapsed or refractory chronic lymphocytic leukemia.
At a glance
| Generic name | Liso-cel |
|---|---|
| Also known as | Lisocabtagene Maraleucel, BREYANZI, JCAR017, Breyanzi®, BMS-986387 |
| Sponsor | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
| Drug class | CAR-T cell therapy |
| Target | CD19 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Liso-cel involves engineering a patient's T lymphocytes to express a chimeric antigen receptor (CAR) targeting CD19, a surface antigen on B cells. Once infused back into the patient, these CAR-T cells proliferate and attack CD19-positive malignant B cells. This approach is designed to induce durable remissions in B-cell hematologic malignancies by leveraging the patient's own immune system.
Approved indications
- Relapsed or refractory large B-cell lymphoma
- Relapsed or refractory chronic lymphocytic leukemia
Common side effects
- Cytokine release syndrome
- Neurological toxicity (CAR-T-related encephalopathy syndrome)
- Cytopenias
- Infections
- Fever
Key clinical trials
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma (PHASE2)
- Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (PHASE2)
- NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (PHASE3)
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PHASE3)
- Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (PHASE1, PHASE2)
- Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome (PHASE2)
- NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liso-cel CI brief — competitive landscape report
- Liso-cel updates RSS · CI watch RSS
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company portfolio CI